Search

Background: \ud We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.\ud \ud Patients and methods: \ud In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-cell lung cancer (sqNSCLC) were explored in 25 and 40 patients, respectively.\ud \ud Results: \ud The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was established as 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28–18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 23 patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76–21.25).\ud \ud Discussion: \ud In this phase I trial, we report a highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC.\ud \ud Clinical trial registration: \ud ClinicialTrials.gov identifier: CNCT02193633.

Aim: Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer deaths in women around the world. Human papilloma virus (HPV) infection is considered necessary factor for the development of cervical cancer and it is identified in 99.7% of cases. The main route of HPV transmission is sexual, and factors such as multiple partners and early onset of sexual activity favors infection and transmission. The incidence of cervical cancer in HIV-positive women is high and it is a defining disease of immunodeficiency syndrome (AIDS). These women also have more aggressive disease that is less responsive to the standard therapy. Viral hepatitis B and C, as well as HIV infection, are sexually transmitted diseases and they share similar risk factors to those of cervical cancer. In the case of hepatitis, they have great importance to public health because of their high prevalence, incidence and possible complications of acute and chronic forms. The objective of this study is to evaluate the prevalence of HIV, hepatitis B and C infection in patients with cervical cancer. Methods: A retrospective search of the database at the Brazilian National Cancer Institute was performed, and all patients diagnosed with cervical cancer between October 2009 and December 2012 and the results of serological tests for HIV, hepatitis B and C infection were analyzed. Results: A total of 1659 women were enrolled. Squamous cervical cancer was diagnosed in 78.6%, adenocarcinoma in 16.8% and less frequent histological subtypes in 4.6%. The median age for first sexual intercourse was 17 years. Number of sexual partners (median) was 3. Positivity for HIV infection was identified in 0.98% (12 patients in 1222 tested). Between patients tested for hepatitis B (n = 1342), positivity for anti-HBc-IgG was 13.85% (n = 186), indicating previous contact with hepatitis virus B. For hepatitis C, 2.18% (n = 31) of the group tested (n = 1422) had anti-HCV positive, and hepatitis C was identified in 15 cases by a confirmatory test. Conclusions: Although the low prevalence of HIV infection, and hepatitis B and C in the cohort analyzed, the possibility of such co-infections should always be evaluated, since those diseases share routes of transmisson and prognosis could be influenced. Disclosure: All authors have declared no conflicts of interest.

Cervical cancer represents a public health problem. Currently, it is the second most common neoplasia worldwide, with approximately 85% of the cases in developing countries. Most of the patients presents with advanced disease. The treatment based on cisplatin and radiotherapy is considered standard to patients with locally advanced cervical cancer, stages IIB to IVA. However, the results are not good enough, especially in stages III e IVA, which shows five-year survival rates of 40 and 15%, respectively. The combination of cisplatin and paclitaxel (CDDP + P) is the standard treatment in first palliative line in several oncology institutions. The replacement of CDDP by carboplatin (C) is regularly done and probably presents less non-hematologic toxicity; however, there is no data in the literature related to the specific efficacy and toxicity to the combination of C + P in this context. At INCA, the combination of C + P has been the standard treatment in first palliative line since August 2008. Objectives To evaluate response rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity of patients with recurrent or metastatic cervical cancer treated with C + P. Material and methods A retrospective analysis of cervical cancer patients treated with C + P in first palliative line at INCA, between August 2008 and January 2010. Results A total of 154 patients were enrolled in the study. The most frequent histology was squamous carcinoma and 51.3 % of the patients were diagnosed as stages III and IV. 50% of the patients received 6 or more cycles of C + P as first palliative line. Objective responses were documented in 35.1% (5.2% complete responses plus 29.9 % partial responses). The median PFS and OS was 4.07 (IC95% 2.8 – 5.3) and 8.4 (IC95% 6.2 – 10.7) months respectively. Hematologic toxicity was the most common: Grade 3 and 4 anemia, neutropenia and thrombocytopenia were 42.2%, 18.1% and - 9.1%, respectively. Conclusion Indirect comparison with published data of the prospective trial using CDDP + P our results were only slightly different, probably related to differences in patients clinical and demographics data. Disclosure All authors have declared no conflicts of interest.